Osimertinib in first-line treatment-is a comparison not proof?

被引：2
|
作者：
Cadranel, Jacques [1 ,2 ,3 ]
机构：
[1] Hop Tenon, AP HP, Chest Dept, Paris, France
[2] Hop Tenon, AP HP, Expert Ctr Thorac Oncol, Paris, France
[3] Pierre & Marie Curie Univ Paris 6, Paris, France
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷 / 03期
关键词：
CELL LUNG-CANCER; OPEN-LABEL; EGFR MUTATIONS; ASIAN PATIENTS; SURVIVAL-DATA; PHASE-III; AFATINIB; GEFITINIB; ERLOTINIB; CHEMOTHERAPY;
D O I：
10.21037/atm.2017.12.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Osimertinib Approved for First-Line Treatment in Metastatic NSCLC
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
  • [2] TAPO in first-line osimertinib therapy and continuation of osimertinib
    Mimura, Chihiro
    Kaneshiro, Kazumi
    Fujimoto, Shodai
    Dokuni, Ryota
    Iwamoto, Natsuhiko
    Matsumura, Kanoko
    Hatakeyama, Yukihisa
    Kono, Yuko
    Tachihara, Motoko
    THORACIC CANCER, 2023, 14 (06) : 584 - 591
  • [3] First-line treatment of ovarian cancer: Proof and promise
    Runowicz, CD
    GYNECOLOGIC ONCOLOGY ISSUES IN THE 8TH IGCS MEETING OF BUENOS AIRES, 2000, : 3 - 6
  • [4] Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
    Osoegawa, Atsushi
    Karashima, Takashi
    Takumi, Yohei
    Sato, Takahiro
    Abe, Miyuki
    Hashimoto, Takafumi
    Sugio, Kenji
    JOURNAL OF THORACIC DISEASE, 2023, 15 (10) : 5566 - 5573
  • [5] Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
    Uchibori, Ken
    Inase, Naohiko
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 915 - 925
  • [6] First-Line Acne Treatment: Efficacy and Comparison of Cost
    McNeil, Michael P.
    Luthy, Karlen E.
    Platt, Christine R.
    Robinson, Michael S.
    Macintosh, Janelle L. B.
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (06):
  • [7] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [8] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Chen, Lanyi Nora
    Lee, Alexandria T. M.
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
  • [9] COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
    Sequist, L. V.
    Peled, N.
    Tufman, A.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1101 - S1101
  • [10] COMPEL: Chemotherapy with/without Osimertinib in Patients with EGFRm advanced NSCLC and Progression on first-line Osimertinib
    Tufman, Autoren A.
    Sequist, L.
    Peled, N.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    de Wit, M.
    PNEUMOLOGIE, 2023, 77 : S8 - S8
12345